Dimitrios Grenzelias HEMATOLOGIST

• Hellenic Association of Haematology

• Rural medical service, 12/1982-4/1984
• Primary urban medical service , 4/1984-12/1984
• 2nd Department of Internal Medicine, University of Athens (Specialty in Internal Medicine), 12/1984-1/1987
• 2nd Department of Internal Medicine, University of Athens (Specialty in Hematology), 1/1987-2/1991
• ΙΚΑ Blood Bank, 1/7/1992-31/12/1992
• Dept. of Clinical hematology, Hygeia Hospital, 10/1992-6/1995
• Department of Medical Oncology St Bartholomew’s Hospital London, 1/7/1995-31/3/1999
• Dept. of Clinical hematology, Hygeia Hospital, 4/1999-6/2000
• Consultant in Hygeia Hospital since June 2000.

Education Experience:

• 2nd Department of Internal Medicine, University of Athens: Participation in education of medical students. 
• Hygeia Hospital, Athens: Education of postgraduate medical students, nurses and technicians. 
• St Bartholomew’s Hospital, London: Education of medical students.
• Participation as invited speaker in education programs in various Haematology departments in Greece. 

Clinical Interest:

• Patients with Hematologic Malignancies (Lymphoma, especially Follicular, Acute and Chronic Leukemia, and Multiple Myeloma treated with conventional chemotherapy and autologous bone marrow transplantation). 

Research Interest:

• Minimal residual disease with molecular technics in Follicular Lymphoma. 
• Post transcription modification of Bcl-2 gene expression in Follicular Lymphoma (Antisense oligonucleotides).
• Genetic predisposition markers in Follicular (TNF gene family mutations).
• Cloning and expression studies of BRL gene involved in Acute Leukemia pathogenesis.

• Scholarship from Greek Scholarship Foundation during the 6 years of my medical studies. 
• Scholarship from Greek Scholarship Foundation for training abroad (Department of Medical Oncology, St Bartholomew’s Hospital, London)
• Member of the scientific committee of 20th Hellenic Hematology Congress.

• Kalmantis T., Vassilaki M., Kalmanti M., Yiagnisis M., Grenzelias D., Spandidos D. (1992). Elevated expression of the Ras p21 oncoprotein in myelodysplastic syn-dromes as determined by immunohistochemical analysis of bone marrow smears. In: Genetics of Haematological Disorders, (Batsocas C and Loucopoulos D Eds.), Washington DC, Hemisphere; pages 163-170

• Kalmanti M, Kalmantis T, Vassilaki M, Galanopoulos A, Grenzelias D, Spandidos DA.The expression of the ras p21 oncoprotein in the bone marrow smears of children with acute leukemia. Anticancer Res. 1992 Nov-Dec; 12(6B): 2177-80
• Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK.Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol. 1999 Nov; 107(2): 388-91
• McCullagh P, Chaplin T, Meerabux J, Grenzelias D, Lillington D, Poulsom R, Gregorini A, Saha V, Young BD.The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukae-mia gene. Oncogene. 1999 Dec 9; 18(52): 7442-52
• Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE, Salam A, Adams K, Norton AJ, Amess JA, Matthews J, Bradburn M, Lister TA, Rohatiner AZ.High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up.J Clin Oncol. 2000 Feb; 18(3): 527-36